Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.35 |
| ▸ | KIT | P10721 | 2/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.35 |
| ▸ | FLT4 | P35916 | 2/20 | 0.35 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1372778 | 0.86 | MET (0.44) | METPDE4BAHRPDGFRBKIT | |
| SCHEMBL1373120 | 0.81 | AHR (0.51) | AHR | |
| SCHEMBL1372752 | 0.81 | MAPT (0.42) | METMAPTPDE4BPDE4DAHR | |
| SCHEMBL1375781 | 0.81 | ALDH1A1 (0.40) | METMAPT | |
| SCHEMBL1376319 | 0.81 | ELANE (0.44) | METMAPTCSF1RPDGFRBKIT | |
| Hydrochloric Acid SCHEMBL1375745 | 0.80 | MAPT (0.42) | METMAPTPDE4BPDE4DAHR | |
| SCHEMBL1375743 | 0.80 | MAPT (0.42) | METMAPTPDE4BPDE4DAHR | |
| SCHEMBL1375986 | 0.80 | MAPT (0.36) | METMAPTCSF1RPDE4BPDE4D | |
| SCHEMBL1373864 | 0.76 | CNR2 (0.42) | — | |
| SCHEMBL1372638 | 0.75 | MAPT (0.46) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2394995-B1 | RING-FUSED 2-PYRIDONE DERIVATIVES AND HERBICIDES | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-8334236-B2 | Ring-fused 2-pyridone derivatives and herbicides | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-12-18 | — | — | US | disclosed |
| EP-2394995-A1 | RING-FUSED 2-PYRIDONE DERIVATIVES AND HERBICIDES | Kumiai Chemical Industry CO., LTD. (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110287937-A1 | RING-FUSED 2-PYRIDONE DERIVATIVES AND HERBICIDES | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110287937-A1 | RING-FUSED 2-PYRIDONE DERIVATIVES AND HERBICIDES | CBR3, CBR1, CHRM1 | MET 1467/4885MAPT 4708/4885CSF1R 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.